UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.025

Sortiert nach

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

The Lancet (British edition), 2016-10, Vol.388 (10056), p.2153-2163

2016

Link zum Volltext

Verfügbarkeit prüfen

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

Journal of clinical oncology, 2016-11, Vol.34 (32), p.3906-3913

2016

Link zum Volltext

Verfügbarkeit prüfen

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

Cancer science, 2018-01, Vol.109 (1), p.174-181

2018

Link zum Volltext

Verfügbarkeit prüfen

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

PloS one, 2017-08, Vol.12 (8), p.e0180939-e0180939

2017

Link zum Volltext

Verfügbarkeit prüfen

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Clinical cancer research, 2012-08, Vol.18 (15), p.4104-4113

2012

Link zum Volltext

Verfügbarkeit prüfen

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials

Endocrine-related cancer, 2019-04, Vol.26 (4), p.391-403

2019

Link zum Volltext

Verfügbarkeit prüfen

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

PloS one, 2018-09, Vol.13 (9), p.e0201005-e0201005

2018

Link zum Volltext

Verfügbarkeit prüfen

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

Neuroendocrinology, 2018-01, Vol.106 (3), p.211-220

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-10, Vol.15 (19), p.6232-6240

2009

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

The New England journal of medicine, 2019-08, Vol.381 (7), p.626-636

2019

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

JAMA oncology, 2016-10, Vol.2 (10), p.1310

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3916-3923

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19

Journal of clinical oncology, 2004-01, Vol.22 (2), p.269-276

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity

Clinical cancer research, 2006-03, Vol.12 (6), p.1760-1767

2006

Link zum Volltext

Verfügbarkeit prüfen

Overcoming kinase resistance in chronic myeloid leukemia

The international journal of biochemistry & cell biology, 2008, Vol.40 (3), p.334-343

2008

Link zum Volltext

Verfügbarkeit prüfen

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures

Epilepsia (Copenhagen), 2018-06, Vol.59 (6), p.1188-1197

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to V. Amoroso et al

Journal of clinical oncology, 2017-05, Vol.35 (13), p.1488-1489

2017

Link zum Volltext

Verfügbarkeit prüfen

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.925-936

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2521-2533

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

Clinical cancer research, 2014-10, Vol.20 (19), p.5032-5040

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of the New Taxane Analog BMS-184476 Given Weekly in Patients with Advanced Malignancies

Clinical cancer research, 2002-09, Vol.8 (9), p.2788-2797

2002

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2004-04, Vol.10 (8), p.2636-2644

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.025

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(882)
Mit Volltextzugriff
(1.485)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Arte
(113)
Rivista Di Filosofia Neo-Scolastica
(51)
Il Foro Italiano
(49)
Aggiornamenti Sociali
(33)
Epidemiologia E Prevenzione
(31)
Giornale Italiano Di Cardiologia
(26)
Rivista Di Filosofia Neoscolastica
(25)
Gregorianum
(24)
Studi Storici
(23)
L'endocrinologo
(22)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19

Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity

Overcoming kinase resistance in chronic myeloid leukemia

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures

Reply to V. Amoroso et al

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

Phase I and Pharmacokinetic Study of the New Taxane Analog BMS-184476 Given Weekly in Patients with Advanced Malignancies

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors

Suchergebnisse filtern